Tag: vobramitamab duocarmazine
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
MacroGenics Pauses Development of Vobramitamab Duocarmazine; Reports Outcomes on other ADC...
MacroGenics has temporarily paused ongoing investments in the development of vobramitamab duocarmazine ('vobra duo,' previously known as MGC018), a B7-H3-targeting ADC with a duocarmycin-based DNA-alkylating payload
